Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
3 Stocks Under $5 With Strong Analyst Upside Potential
08:41am, Tuesday, 24'th Feb 2026
At a time when many investors are rotating out of speculative penny stocks, others continue to embrace the risk-reward dynamic. Stocks that trade for under $5 carry a certain amount of risk.
Vaxart (OTCMKTS:VXRT) Stock Price Passes Above Fifty Day Moving Average – What’s Next?
04:56am, Tuesday, 24'th Feb 2026
Shares of Vaxart, Inc. (OTCMKTS:VXRT - Get Free Report) passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $0.53 and traded as high as $0.6
NEW YORK--(BUSINESS WIRE)--Hagens Berman Sobol Shapiro LLP & Scott+Scott Attorneys at Law LLP: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA In re VAXART, INC. SECURITIES LITIGATION Thi
The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)
09:40am, Sunday, 18'th Jan 2026
Penny stocks attract speculative investors looking for high-risk/high-reward opportunities. That means looking for companies with disruptive technologies, that are part of an emerging trend, or ones t
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
04:01pm, Thursday, 08'th Jan 2026
SOUTH SAN FRANCISCO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart or “the Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill v
Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average – Time to Sell?
03:14am, Thursday, 25'th Dec 2025
Vaxart, Inc. (NASDAQ: VXRT - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.39 and traded as low as $
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
09:28pm, Tuesday, 18'th Nov 2025
Vaxart, Inc. (OTC:VXRT) Shareholder/Analyst Call November 18, 2025 4:30 PM EST Company Participants Steven Lo - President, CEO & Director Jeroen Grasman - CFO, Principal Accounting Officer & Principal
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
10:41pm, Thursday, 13'th Nov 2025
Vaxart, Inc. (OTC:VXRT) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Edward Berg - Senior VP & General Counsel Steven Lo - President, CEO & Director James Cummings - Chief
Vaxart to Host Upcoming Conference Calls
08:00am, Friday, 07'th Nov 2025
Third quarter 2025 results conference call to be held on November 13 at 4:30 p.m. ET Stockholder fireside chat to be held on November 18 at 4:30 p.m.
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
04:01pm, Wednesday, 05'th Nov 2025
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors aut
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
04:00pm, Wednesday, 05'th Nov 2025
Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continu
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
08:00am, Wednesday, 08'th Oct 2025
SOUTH SAN FRANCISCO, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombi
Vaxart Appoints W. Mark Watson as Lead Independent Director
04:05pm, Wednesday, 17'th Sep 2025
In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
04:54pm, Wednesday, 10'th Sep 2025
- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study -
Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting
09:00am, Wednesday, 10'th Sep 2025
Question Board's Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes
